Literature DB >> 1444300

Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci.

E Cercenado1, G M Eliopoulos, C B Wennersten, R C Moellering.   

Abstract

The emergence of clinical enterococcal isolates resistant to both ampicillin and vancomycin is a cause of great concern, as there are few therapeutic alternatives for treatment of infections caused by such organisms. We evaluated the effects of the combination of ampicillin with vancomycin against vancomycin-resistant clinical enterococcal isolates. Using both the checkerboard technique and time-kill curves, we examined 28 strains of enterococci (17 Enterococcus faecalis and 11 Enterococcus faecium strains) with different levels of resistance to vancomycin. Of these, 15 strains were also highly gentamicin resistant, and 9 demonstrated resistance to ampicillin. Only seven strains of E. faecalis were inhibited synergistically by the combination of vancomycin with ampicillin, and even then, the concentrations of vancomycin at which synergism was demonstrated were above levels achievable in serum. None of the ampicillin-resistant isolates (all E. faecium) were inhibited synergistically at any concentration of the drugs. In no instance was bactericidal synergism observed, and in most cases the combination resulted in less killing than with ampicillin alone. Antagonism was not observed at clinically relevant concentrations. The results of this study suggest that the combination of vancomycin with ampicillin has little to offer against these emerging pathogens.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1444300      PMCID: PMC245476          DOI: 10.1128/AAC.36.10.2201

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin.

Authors:  D M Shlaes; L Etter; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

2.  Concomitant high-level vancomycin and penicillin resistance in clinical isolates of enterococci.

Authors:  S Handwerger; D C Perlman; D Altarac; V McAuliffe
Journal:  Clin Infect Dis       Date:  1992-03       Impact factor: 9.079

3.  In vitro synergism between daptomycin and fosfomycin against Enterococcus faecalis isolates with high-level gentamicin resistance.

Authors:  L B Rice; G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

4.  In vitro susceptibility studies of vancomycin-resistant Enterococcus faecalis.

Authors:  D F Sahm; J Kissinger; M S Gilmore; P R Murray; R Mulder; J Solliday; B Clarke
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

5.  Effects of combinations of beta-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci.

Authors:  R Leclercq; E Bingen; Q H Su; N Lambert-Zechovski; P Courvalin; J Duval
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

6.  Increasing resistance to beta-lactam antibiotics among clinical isolates of Enterococcus faecium: a 22-year review at one institution.

Authors:  M L Grayson; G M Eliopoulos; C B Wennersten; K L Ruoff; P C De Girolami; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

7.  Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside.

Authors:  G M Eliopoulos; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

  7 in total
  17 in total

1.  Synergy testing of vancomycin-resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents.

Authors:  S O Matsumura; L Louie; M Louie; A E Simor
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 2.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

3.  Vancomycin-Resistant Enterococcus: Infectious Endocarditis Treatment.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

Review 4.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 5.  Genetics and mechanisms of glycopeptide resistance in enterococci.

Authors:  M Arthur; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

6.  Rapid detection of vancomycin-resistant enterococci.

Authors:  S C Edberg; C J Hardalo; C Kontnick; S Campbell
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

7.  Synergy and resistance to synergy between beta-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of Enterococcus faecium.

Authors:  L Gutmann; S al-Obeid; D Billot-Klein; M L Guerrier; E Collatz
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

8.  Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.

Authors:  Christian Joukhadar; Satish Pillai; Christine Wennersten; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

9.  Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations.

Authors:  M K Hayden; G I Koenig; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

10.  Genetic basis for vancomycin-enhanced cephalosporin susceptibility in vancomycin-resistant enterococci revealed using counterselection with dominant-negative thymidylate synthase.

Authors:  Christopher J Kristich; Dusanka Djorić; Jaime L Little
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.